{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:04:14Z","timestamp":1768230254010,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"DOI":"10.7759\/cureus.101337","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:55:40Z","timestamp":1768218940000},"source":"Crossref","is-referenced-by-count":0,"title":["The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh"],"prefix":"10.7759","author":[{"given":"Pooja","family":"Unnikrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami","family":"Vijayashree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip Chandra","family":"Chintada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Khatija Begum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Gullipalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sriya","family":"Chalamalasetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/v16121896","article-title":"Pemphigus and bullous pemphigoid following COVID-19 vaccination: a systematic review","volume":"16","author":"Martora F","year":"2024","unstructured":"Martora F, Battista T, Potestio L, Napolitano M, Patruno C, Megna M, D'Agostino M. Pemphigus and bullous pemphigoid following COVID-19 vaccination: a systematic review. Viruses. 2024, 16:6. 10.3390\/v16121896","journal-title":"Viruses"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18030","article-title":"Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19","volume":"36","author":"Kasperkiewicz M","year":"2022","unstructured":"Kasperkiewicz M, Woodley DT. Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19. J Eur Acad Dermatol Venereol. 2022, 36:e498-500. 10.1111\/jdv.18030","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1293920","article-title":"New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies","volume":"11","author":"Ghanaatpisheh A","year":"2024","unstructured":"Ghanaatpisheh A, Safari M, Haghshenas H, et al.. New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies. Front Med (Lausanne). 2024, 11:1293920. 10.3389\/fmed.2024.1293920","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-00971-8","article-title":"Pemphigus vulgaris after COVID-19 infection: a case of disease induction","volume":"3","author":"De Medeiros VL","year":"2021","unstructured":"De Medeiros VL, Monteiro-Neto AU, Fran\u00e7a DD, Castelo Branco R, de Miranda Coelho \u00c9O, Takano DM. Pemphigus vulgaris after COVID-19 infection: a case of disease induction. SN Compr Clin Med. 2021, 3:1768-72. 10.1007\/s42399-021-00971-8","journal-title":"SN Compr Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19456","article-title":"Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia","volume":"38","author":"Huynh J","year":"2024","unstructured":"Huynh J, Leiter U, Garbe C, et al.. Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. J Eur Acad Dermatol Venereol. 2024, 38:84-92. 10.1111\/jdv.19456","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18967","article-title":"Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid","volume":"37","author":"Solimani F","year":"2023","unstructured":"Solimani F, Mesas-Fern\u00e1ndez A, Bodner E, et al.. Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid. J Eur Acad Dermatol Venereol. 2023, 37:e695-7. 10.1111\/jdv.18967","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.063","article-title":"COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: a large-scale population-based cohort study of 112 million individuals","volume":"92","author":"Curman P","year":"2025","unstructured":"Curman P, Kridin K, Zirpel H, et al.. COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: a large-scale population-based cohort study of 112 million individuals. J Am Acad Dermatol. 2025, 92:452-63. 10.1016\/j.jaad.2024.10.063","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568801","article-title":"Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study","volume":"16","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Huang D, Shi Y, Ding Y, Gao Y. Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study. Front Immunol. 2025, 16:1568801. 10.3389\/fimmu.2025.1568801","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16872","article-title":"Epidemiology, clinical profiles, and prognostic value of COVID-19-related cutaneous manifestations in African populations: a rapid narrative review","volume":"63","author":"Nyasulu PS","year":"2024","unstructured":"Nyasulu PS, Tamuzi JL. Epidemiology, clinical profiles, and prognostic value of COVID-19-related cutaneous manifestations in African populations: a rapid narrative review. Int J Dermatol. 2024, 63:10-22. 10.1111\/ijd.16872","journal-title":"Int J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2021.01.007","article-title":"Impact of COVID-19 on autoimmune blistering diseases","volume":"39","author":"Drenovska K","year":"2021","unstructured":"Drenovska K, Vassileva S, Tanev I, Joly P. Impact of COVID-19 on autoimmune blistering diseases. Clin Dermatol. 2021, 39:359-68. 10.1016\/j.clindermatol.2021.01.007","journal-title":"Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050465","article-title":"New onset and exacerbation of autoimmune bullous dermatosis following COVID-19 vaccination: a systematic review","volume":"12","author":"Wu PC","year":"2024","unstructured":"Wu PC, Huang IH, Wang CY, Chi CC. New onset and exacerbation of autoimmune bullous dermatosis following COVID-19 vaccination: a systematic review. Vaccines (Basel). 2024, 12:5. 10.3390\/vaccines12050465","journal-title":"Vaccines (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20906","article-title":"COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation","volume":"186","author":"Kasperkiewicz M","year":"2022","unstructured":"Kasperkiewicz M, Strong R, Mead K, Yale M, Zillikens D, Woodley DT, Recke A. COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. Br J Dermatol. 2022, 186:737-9. 10.1111\/bjd.20906","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko MM","year":"2021","unstructured":"Tomayko MM, Damsky W, Fathy R, et al.. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021, 148:750-1. 10.1016\/j.jaci.2021.06.026","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1112823","article-title":"Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine","volume":"10","author":"Pira A","year":"2023","unstructured":"Pira A, Sinagra JL, Moro F, Mariotti F, Di Zenzo G. Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine. Front Med (Lausanne). 2023, 10:1112823. 10.3389\/fmed.2023.1112823","journal-title":"Front Med (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17891","article-title":"Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review","volume":"36","author":"Pauluzzi M","year":"2022","unstructured":"Pauluzzi M, Stinco G, Errichetti E. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review. J Eur Acad Dermatol Venereol. 2022, 36:e257-9. 10.1111\/jdv.17891","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18673","article-title":"Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab","volume":"37","author":"Baffa ME","year":"2023","unstructured":"Baffa ME, Maglie R, Montefusco F, Pipit\u00f2 C, Senatore S, Antiga E. Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab. J Eur Acad Dermatol Venereol. 2023, 37:e135-7. 10.1111\/jdv.18673","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13092129","article-title":"Autoimmune skin diseases in the era of COVID- 19: pathophysiological insights and clinical implications","volume":"13","author":"Liakou AI","year":"2025","unstructured":"Liakou AI, Routsi E, Plisioti K, et al.. Autoimmune skin diseases in the era of COVID- 19: pathophysiological insights and clinical implications. Microorganisms. 2025, 13:9. 10.3390\/microorganisms13092129","journal-title":"Microorganisms"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X251357053","article-title":"New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report","volume":"13","author":"Badawod E","year":"2025","unstructured":"Badawod E. New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report. SAGE Open Med Case Rep. 2025, 13:3. 10.1177\/2050313X251357053","journal-title":"SAGE Open Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-023-04146-y","article-title":"Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series","volume":"17","author":"Rasner CJ","year":"2023","unstructured":"Rasner CJ, Schultz B, Bohjanen K, Pearson DR. Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series. J Med Case Rep. 2023, 17:408. 10.1186\/s13256-023-04146-y","journal-title":"J Med Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1117176","article-title":"Autoimmune blistering skin diseases triggered by COVID-19 vaccinations: an Australian case series","volume":"9","author":"Cowan TL","year":"2022","unstructured":"Cowan TL, Huang C, Murrell DF. Autoimmune blistering skin diseases triggered by COVID-19 vaccinations: an Australian case series. Front Med (Lausanne). 2022, 9:1117176. 10.3389\/fmed.2022.1117176","journal-title":"Front Med (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446703-the-changing-trends-in-the-incidence-and-clinical-presentation-of-immunobullous-disorders-before-and-during-the-covid-19-era-in-a-tertiary-healthcare-centre-in-andhra-pradesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:55:41Z","timestamp":1768218941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446703-the-changing-trends-in-the-incidence-and-clinical-presentation-of-immunobullous-disorders-before-and-during-the-covid-19-era-in-a-tertiary-healthcare-centre-in-andhra-pradesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.101337","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}